Wilms' tumor gene 1 (WT1) is a transcription factor involved in developmental processes. In adult hematopoiesis, only a small portion of early progenitor cells express WT1, whereas most leukemias show persistently high levels, suggesting an oncogenic role. We have previously characterized oncogenic BCR/ ABL1 tyrosine kinase signaling pathways for increased WT1 expression. In this study, we show that overexpression of BCR/ ABL1 in CD34 þ progenitor cells leads to reduced expression of interferon regulatory factor 8 (IRF8), in addition to increased WT1 expression. Interestingly, IRF8 is known as a tumor suppressor in some leukemias and we investigated whether WT1 might repress IRF8 expression. When analyzed in four leukemia mRNA expression data sets, WT1 and IRF8 were anticorrelated. Upon overexpression in CD34 þ progenitors, as well as in U937 cells, WT1 strongly downregulated IRF8 expression. All four major WT1 splice variants induced repression, but not the zinc-finger-deleted WT1 mutant, indicating dependence on DNA binding. A reporter construct with the IRF8 promoter was repressed by WT1, dependent on a putative WT1-response element. Binding of WT1 to the IRF8 promoter was demonstrated by chromatin immunoprecipitation. Our results identify IRF8 as a direct target gene for WT1 and provide a possible mechanism for oncogenic effects of WT1 in leukemia.
Introduction
Wilms' tumor gene 1 (WT1) encodes a DNA-binding zincfinger transcription factor necessary for the development of various organs and structures in the fetus (reviewed in Lee and Haber 1 and in Scharnhorst et al. 2 ). Expression of WT1 in a small fraction of early progenitor cells in human and murine adult hematopoiesis, [3] [4] [5] [6] [7] [8] as well as analysis of WT1-deficient murine progenitors showing impaired reconstitution of hematopoiesis in vivo, 9 indicate a role for WT1 in maintaining proliferation and/or survival of hematopoietic cells. Consistent with this notion, overexpression of WT1 alone in myeloid progenitors induced a myeloproliferative-like disorder in mice, 10 and coexpression of WT1 and the fusion protein AML1-ETO resulted in a rapid development of acute leukemia, 10 lending further support for the role of WT1 as an oncogene in leukemia.
High levels of WT1 are detected in most cases of chronic and acute human leukemia, [11] [12] [13] [14] as well as in most leukemic cell lines. Whereas endogenous WT1 is downregulated after induced differentiation of cell lines, overexpression of WT1 often interferes with differentiation. [15] [16] [17] Thus, a large amount of data indicates a leukemogenic role of WT1. Despite the fact that some target genes of WT1 have been suggested (reviewed in Yang et al. 18 ), the mechanisms through which WT1 exerts its leukemogenic effects remain unclear.
Interferon regulatory factor 8 (IRF8), also designated ICSBP (interferon consensus sequence-binding protein), belongs to the IRF family of transcription factors and is normally expressed in hematopoietic cells, including monocytes, macrophages and subsets of lymphocytes, showing inducibility by a-and g-interferon (reviewed in Tamura et al 19 ) . In late myeloid differentiation, IRF8 participates in the commitment to macrophage differentiation and is important for the function of mature macrophages, and several IRF8 target genes in developing macrophages have been identified. 19 In contrast to the almost ubiquitously high expression of WT1 in leukemias, the expression of IRF8 is very low or absent in most leukemias. 20 Interestingly, elimination of IRF8 in transgenic mice results in a systemic expansion of granulocytes with later transition into blast crisis, a development very similar to human chronic myeloid leukemia (CML). 21 Similar hematopathological disturbances, although in milder forms, were also observed after heterozygous elimination of IRF8, indicating haploid insufficiency of IRF8. 21 The importance of reduced levels of IRF8 in the pathogenesis of CML is further underscored by the observation that forced expression of IRF8 counteracts the BCR/ ABL1-induced leukemic phenotype in vivo 22 and in vitro. 23, 24 Besides its association with the development of CML, a role of IRF8 is also implicated in acute leukemogenesis; in murine models for acute leukemia, IRF8 acts as a tumor suppressor, the loss of which cooperates with leukemogenic fusion genes NUP98-TOP1 or AML1-ETO, 25, 26 with the oncogenic SHP2 tyrosine phosphatase 27 and with loss of neurofibromin 1.
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Antiproliferative mechanisms downstream of IRF8 may include upregulation of p15INK4b, 29 but the mechanism by which the level of IRF8 is regulated within the context of leukemia is unknown.
In this study, we report that the WT1 protein, frequently overexpressed in leukemia, can directly repress transcription of the IRF8 gene, thus providing a novel mechanism by which WT1 might contribute to leukemogenesis.
Materials and methods

Cell culture
Umbilical cord blood was, after ethical approval and informed consent, collected from mothers giving birth to normal full-term infants, from which mononuclear cells were isolated by separation on Lymphoprep (Nycomed Pharma, Oslo, Norway), and CD34 þ cells were enriched by labeling with magnetic beads (CD34 Progenitor Cell Isolation Kit, Miltenyi Biotec, Bergisch-Gladbach, Germany) according to the manufacturer's instructions. CD34 þ cell purity was always 490% as determined by flow cytometry. 293T/17 (American Type Culture Collection, Manassas, VA, USA) cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum. U937 cells were obtained from the German Collection of Microorganisms and Cell Cultures (Braunschweig, Germany). The CML cell lines KU812, LAMA-84 and JK-1 cells were kindly donated by Dr Thoas Fioretos (Clinical Genetics, Lund University, Lund, Sweden). Both U937 and CML cell lines were maintained in RPMI 1640 supplemented with 10% fetal calf serum.
RNA isolation, reverse transcription and RT-qPCR
To analyze the expression of WT1 and IRF8 mRNA, total RNA was isolated using the RNeasy Mini Kit or RNeasy Micro Kit according to the manufacturer's protocol (Qiagen Gmbh, Hilden Germany). A total of 200 ng of total RNA was reverse transcribed using High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems Inc., Foster City, CA, USA) with random hexamer primers according to the manufacturer's instructions. In some experiments with BCR/ABL1-transduced CD34 þ cells, 500 GFP þ cells were sorted directly (by a FACS Aria, BD, Franklin Lakes, NJ, USA) into PCR tubes containing cell lysis buffer, after which reverse transcription (RT) reaction was performed using the Sensiscript RT kit (Qiagen) as described elsewhere. 30 Quantitative PCR (qPCR) was carried out using TaqMan probe-based chemistry (Applied Biosystems). The probes for the WT1 (Hs00240913_m1), IRF1 (Hs00971960_m1), IRF4 (Hs00277069_m1) IRF8 (Hs00175238_m1), ISG15 (interferon-stimulated gene 15) (Hs01921425_s1) and the endogenous controls 18S (Hs99999901_s1) and GAPDH (glyceraldehyde-3-phosphate dehydrogenase, Hs99999905_m1) were purchased as Assay-onDemand (Applied Biosystems). The amplification reactions were all performed in triplicates in an ABI Prism 7000 Sequence Detection System (Applied Biosystems) according to the manufacturer's instructions, except when analyzing gene expression from only 500 cells, in which case cDNA in 5 ml of the RT reaction was used in each 25 ml PCR reaction, as described elsewhere. 30 Data were collected and analyzed using the Sequence Detector v.1.1 software (Applied Biosystems). Relative quantitative data based on the DDC T method 31 was calculated. Normalization:
. Efficacy of the PCR amplifications of controls and tests was identical; parallelism of standard curves of the control and test was confirmed.
Western blot analysis
Western blotting was performed using the following primary antibodies: WT1(180) sc-846, ICSBP(c-19) sc-6058, Actin(c-2) sc-8432, GAPDH (6C5) sc-32233, all from Santa Cruz Biotechnology (Santa Cruz, CA, USA). All antibodies were diluted in a ratio of 1:500. Starting block blocking buffer (Pierce, Rockford IL, USA) was used in the incubation steps with primary and secondary antibodies. The following secondary antibodies were used: goat-anti-rabbit-horseradish peroxidase 172-1019, goat-anti-mouse-horseradish peroxidase 170-6516 and rabbit anti-sheep-horseradish peroxidase 172-1017, all from Bio-Rad Laboratories (Hercules, CA, USA). Each lane was loaded with material corresponding to 300 000 CD34 þ cells or 30 000 U937 cells. Cloning and site-directed mutagenesis of IRF8 promoter Transient transfections and luciferase-reporter assays cDNA encoding WT1( þ 17 amino acid (AA)/ÀKTS) (KTS denoting lysine, threonine, serine) was amplified by PCR from pCMV-CB6 þ /WT1( þ 17AA, ÀKTS) (kindly provided by Dr F Rauscher III, Philadelphia, PA, USA) and cloned into pcDNA3 (Invitrogen) (EcoRI/EcoRV). In triplicates, 100 ng of the IRF8 promoter reporter construct and 500 ng of pcDNA3 or pcDNA3/ WT1 ( þ 17AA/ÀKTS) were cotransfected into 250 000 293T/17 cells in 24-well plates using the Polyfect Kit (Qiagen) according to the manufacturer's instructions. After 48 h, the cells were lysed and subjected to luciferase assay. Cell lysis and luciferase assay were performed using the Dual luciferase reporter assay kit (Promega) and a Glomax 20/20 luminometer (Turner Designs, Sunnyvale, CA, USA) according to the manufacturers' instructions. Normalization of firefly luciferase values for transfection efficiency could not be performed because of systematic stimulatory effects exerted by WT1 on Renilla luciferase expression.
Chromatin immunoprecipitation analysis
Chromatin immunoprecipitation (ChIP) was performed using Low cell ChIP kit from Diagenode (Sparta, NJ, USA) according to manufacturer's instructions. Briefly, CD34 þ cells were retrovirally transduced with a vector expressing WT1( þ /À) or empty MIG vector. Forty-eight hours after transduction, 300 000 cells were fixed with formaldehyde and used in the subsequent immunoprecipitation. In all, 2 mg of WT1 antibody (C-19, sc-192 or F-6, sc-7385, Santa Cruz Biotechnology), or no antibody as negative control, was used in each precipitation. The precipitated DNA was analyzed in triplicate with qPCR (Applied Biosystems 7500), using Power SyBRgreen chemistry (Applied Biosystems). Relative quantitative data based on the DDC T WT1 protein represses IRF8 K Vidovic et al method. 31 were calculated. Normalization: 
Microarray data sets
We used microarray data from the study by Valk et al. 32 (adult acute myeloid leukemia (AML), mixed cytogenetic subtypes, n ¼ 232, from NCBI GEO, accession no. GSE1159), the study by Metzeler et al. 33 (adult AML, normal karyotype, n ¼ 162, from NCBI GEO, accession no. GSE12417), the study by Verhaak et al. 34 (adult AML, mixed cytogenetic subtypes, n ¼ 461, from NCBI GEO, accession no. GSE6891) and the study by Zheng et al. 35 (chronic and blast phase CML, n ¼ 11, from ArrayExpress, accession no. E-MEXP-480). All data were transformed to the log2 scale. To compute the correlation between WT1 and IRF8, we used the standard Pearson correlation coefficient.
Results
Expression of the BCR/ABL1 fusion in CD34 þ increases expression of WT1 and decreases expression of IRF8
We have previously characterized a signaling pathway from BCR/ABL1 leading to increased transcription of the WT1 gene and increased levels of WT1 protein, conferring increased resistance to imatinib-induced cell death. 36 Interestingly, the tumor suppressor IRF8 is downregulated in a murine model of BCR/ABL1-induced myeloproliferative disease. 22 We therefore investigated whether the expression of IRF8, in addition to WT1, was affected in human progenitors overexpressing BCR/ABL1. Human CD34 þ cord blood cells were retrovirally transduced with human BCR/ABL1 as described previously, 36 and the expression of IRF8 was analyzed by RT-qPCR at 24 h after transduction. Indeed, the levels of IRF8 mRNA ( Figure 1a ) and IRF8 protein ( Figure 1b) were strongly reduced in BCR/ABL1-expressing progenitor cells. As previously reported, 36 WT1 mRNA and protein was increased in response to BCR/ABL1 (Figures 1a and b) . These data confirm and extend previous results 22, 36, 37 and made us hypothesize that WT1 downmodulates the expression of IRF8.
A negative correlation between WT1 and IRF8 expression
Although WT1 is strongly expressed in most leukemias, [11] [12] [13] [14] levels of IRF8 are reported to be low or absent. 20 To gain support for the notion of a WT1-induced downmodulation of IRF8 expression, we analyzed mRNA levels in different leukemic cell lines. Most cell lines were expressing WT1, whereas the IRF8 expression was low or undetectable, especially in the CML cell lines K562, KU812, LAMA-84 and JK-1, and also in the AML cell line HEL. Furthermore, the lymphoma cell lines Namalwa and Ramos expressed moderate IRF8 mRNA levels but had no detectable WT1 mRNA levels (data not shown). Next, we extended the analysis of the correlation between WT1 and IRF8 to primary AML and CML samples by analyzing the expression pattern of WT1 and IRF8 mRNA in microarray data sets. We compiled a compendium of gene expression profiles of primary myeloid leukemias (as described in the 'Materials and methods' section). In total, we retrieved 866 Affymetrix U133A or U133A þ B gene expression profiles (Affymetrix, Santa Clara, CA, USA) from three studies on adult AML and one study on CML. In the AML data sets, we observed a highly significant anticorrelation between the expression of WT1 and IRF8 (r ¼ À0.36, P ¼ 5.8 Â 10 À9 in GSE1159; r ¼ À0.48, P ¼ 2.6 Â 10 À28 in GSE6891; and r ¼ À0.43, P ¼ 3.7 Â 10 À9 ) in GSE12417. An anticorrelation was also present in the CML data set (r ¼ À0.72, P ¼ 0.00019). We conclude that the expression of WT1 and IRF8 are anticorrelated both in cell lines and in primary human leukemias, compatible with the notion of WT1 as a repressor of IRF8. 
Forced expression of WT1 inhibits IRF8 expression
To investigate whether WT1 can repress mRNA expression of IRF8, human CD34 þ progenitor cells were retrovirally transduced with WT1 as described previously, 36 after which IRF8 expression was determined. As shown in Figure 2a , expression of WT1 reduced IRF8 expression to 20-30% of that observed in control cells. The reduction of IRF8 mRNA correlated with a decrease in IRF8 protein levels, as determined by immunoblotting with an anti-IRF8 antibody (IRF8(c-19) , Santa Cruz Biotechnology) (Figure 2b ). The decrease of IRF8 protein was also verified with another IRF8 antibody (AF5117, R&D Systems Inc., Minneapolis, MN, USA) (data not shown). There are four major isoforms of WT1, including or excluding a 17 amino-acid insert (17AA) in the amino-terminal part, and a 3 amino-acid insert (KTS) between zinc-fingers 2 and 3 in the carboxyterminal part of the protein. Although the KTS insert can affect DNA binding, the 17AA insert may modulate the transactivation exerted by WT1 (reviewed in Lee and Haber 1 and in Scharnhorst et al 2 ). To investigate whether the repressive effect of WT1 on IRF8 expression was specific for certain isoforms of WT1, we
in leukemic U937 cells lacking endogenous WT1 protein, but with high expression of IRF8. WT1delZ, lacking the entire carboxyterminal zinc-finger domain and thus with interrupted DNA-binding capacity, was used as a negative control. WT1 þ /À and WT1À/ þ showed the strongest effects, reducing IRF8 expression to B40% of that in control (Figure 3a) . WT1 þ / þ , and in particular WT1À/À, were less effective. WT1delZ did not affect levels of IRF8, indicating dependence on DNA binding for repression of IRF8 (Figure 3a) . We conclude that WT1 represses IRF8 expression in normal progenitors and in leukemic cells, and that the strongest repression is mediated by the WT1 þ /À splice variant.
The repression of IRF8 is not due to general inhibition of interferon signaling IRF8 expression is strongly induced in response to interferon-g, and also to a lesser extent by interferon-a. 22 Any interference with interferon signaling thus could have a negative impact on IRF8 expression. Interestingly, a functional interaction between STAT3, involved in interferon signaling, and WT1 has been reported. 38 We therefore wanted to investigate whether WT1 induced a general repression of interferon-responsive genes.
To that end, we determined the expression of IRF1, IRF4 and ISG15, all well characterized interferon-induced genes (reviewed in Tamura et al. 19 ), in response to WT1 þ /À in U937 cells. Interestingly, none of these genes responded with repression in response to WT1. Rather, some WT1 isoforms upregulated the expression of IRF1, IRF4 and ISG15 (Figures 3b  and c) . To assure that similar amounts of WT1 protein were expressed in the cells, a western blot analysis of WT1 was performed, showing comparable levels of the different isoforms (Figure 3e ). Upon expression of WT1 þ /À, a band corresponding to WT1delZ occurred (Figure 3e) , the identity of which is not clear, but it could hypothetically indicate processing of WT1 þ /À into the delZ form. Importantly, it does not affect the main conclusion that WT1 represses IRF8, as repression is a common effect among the full-length WT1 variants. We conclude that the WT1-induced repression is not a result of a general inhibition of interferon-responsive genes, but rather is specific for IRF8.
WT1 expression does not affect the methylation of the IRF8 promoter
Recent data indicate that IRF8 expression may be silenced by promoter methylation in carcinomas. [39] [40] [41] In AML, 7 out of 21 analyzed samples showed signs of promoter methylation. 42 However, high expression of IRF8 in the presence of methylated promoter has been reported for leukemic cell lines. 43 To investigate whether WT1-induced repression of IRF8 correlated with increased methylation of the IRF8 gene, we performed bisulfite sequencing of DNA from human progenitor cells transduced with WT1. A 256 bp CpG-rich region of the promoter, À564 to À278, was analyzed. This region was chosen as it is methylated in some solid cancers. 40, 41 As shown in Figure 4 , the analyzed part of the IRF8 promoter was almost completely unmethylated both in the absence or presence of WT1, in spite of reduced IRF8 levels (Figure 2a) . In contrast, U937 cells showed 494% methylation, consistent with a previous report. 43 Although we cannot exclude that long-lasting repression of the IRF8 gene may lead to methylation, we conclude that immediate WT1-induced repression of IRF8 is not due to increased methylation of the IRF8 gene.
WT1 represses IRF8 promoter activity
Next, we investigated whether WT1 affects IRF8 promoter activity. In human hematopoietic cells, one major transcription start site is used. 43 We investigated the human promoter and its WT1 protein represses IRF8 K Vidovic et al possible regulation by WT1 through cloning of the proximal sequence upstream of the transcription start site (À970 to þ 74) into the luciferase reporter pGL3 as described in the 'Materials and methods' section, after which reporter transfections were performed in 293T/17 cells, in which the activity of the promoter in response to overexpressed WT1 was determined. Cotransfection with WT1 þ /À resulted in a modest repression (23%) of promoter activity ( Figure 5 ), indicating binding of WT1. Inspection of the promoter sequence using MatInspector (Genomatix, Munich, Germany; http://www.genomatix.de) indicated a possible WT1-binding site at position À52 to À38. This site was mutated to abolish WT1 binding, as described in the 'Materials and methods' section, after which the promoter constructs were used in reporter transfection assays. Importantly, mutated promoter was completely unresponsive to repression from overexpression of WT1 (Figure 5 ), supporting the conclusion that WT1 can bind to the nonmutated promoter and repress transcription.
WT1 binds to the IRF8 promoter
To gain evidence for binding of WT1 to the indicated part of the promoter, we performed ChIP analysis. CD34 þ cells were transduced with WT1 þ /À and 48 h after transduction ChIP was performed, followed by qPCR amplification of the promoter region containing the WT1-binding site (À52 to À38) (WT1 site). qPCR amplification of a region 3 kbp downstream of the binding site (3 kb d.s.) was used as negative control. Two distinct WT1-specific antibodies were used separately in the immunoprecipitation step, to verify the specificity of the ChIP analysis. 
WT1 protein represses IRF8
K Vidovic et al
Precipitation with either antibody resulted in a three-to eightfold enrichment of IRF8 promoter DNA containing the WT1-binding site ( Figure 6 ). In contrast, no enrichment of control DNA 3 kbp downstream of the transcription start was detected ( Figure 6 ). No DNA amplification signal could be detected after negative control immunoprecipitation using no antibody (data not shown).
Discussion
The main conclusion in this study is that the transcription factor WT1 can bind to the promoter of the IRF8 gene and repress its transcription, thus reducing expression of IRF8. This conclusion is based on several findings that: (1) expression of WT1 resulted in a decrease of IRF8 mRNA and protein levels in CD34 þ progenitor cells, as well as in leukemic U937 cells; (2) repression was dependent on DNA binding of WT1, as the WT1 (delZ) mutant, with no DNA-binding capacity, showed no effect on IRF8 expression; (3) that a promoter reporter was repressed by WT1, dependent on a potential WT1-binding site in the promoter; and (4) WT1 binds to the promoter, as judged by ChIP. Moreover, statistic analysis of expression levels of WT1 and IRF8 in leukemia data sets showed an anticorrelation 0 -CpG-3 0 dinucleotides, in the region À564 to À278 of the IRF8 proximal promoter, were analyzed. Four distinct clones from each cell type were analyzed. The overall bisulfite conversion efficiency rate was 494%. WT1 protein represses IRF8 K Vidovic et al between WT1 and IRF8 in AML and CML samples, both with and without known genetic aberrations, with a robust negative correlation, r ¼ À0.36 to r ¼ À0.72 depending on the magnitude of the data sets. It is noteworthy that when compared with WT1, IRF8 was among the most anticorrelated genes in the evaluated gene lists: 50th of 54 614 gene probes (GSE6891), 138th of 44 693 (GSE12417) and 249th of 22 216 (GSE1159). We also found that high WT1 levels anticorrelated with low amounts of IRF8 transcripts in clinical CML samples. 35 Thus, experimental data, and expression patterns in primary leukemia samples, support the conclusion that WT1 can mediate repression of IRF8.
What is the molecular mechanism for WT1-mediated repression of IRF8? The transcription factor STAT1 has been linked to interferon-induced expression of IRF8, mediated by a STAT1-responsive element in close proximity of the currently identified WT1-response element. 41 A functional interaction between WT1 and STAT3 is reported, 38 giving rise to the question whether WT1 affects IRF8 expression by interference with STAT1. However, we found that the effect of WT1 is specific for IRF8 among interferon-responsive genes, as the levels of IRF1, IRF4 and ISG15 in transduced cells were not decreased. Rather, some isoforms of WT1 induced increased expression of these genes, arguing against an inhibition of STAT1 signaling as the mechanism for WT1-mediated repression of IRF8. The indication that WT1 might upregulate IRF1, IRF4 and ISG15 was however not corroborated when expression levels were investigated in leukemic cell lines or in leukemic mRNA expression data sets (data not shown), indicating that upregulation of these genes by WT1 is not a general phenomenon.
In some cases of carcinoma, the tumor suppressor IRF8 is silenced by strong methylation of the promoter, 39, 41 leading to perturbed response to INFg. 44 The methylation status of the proximal promoter near the transcription start site of IRF8 was previously investigated in U937 cells. In this cell line, active transcription of IRF8 occurs from a methylated IRF8 promoter, 43 questioning methylation of the proximal IRF8 promoter as an important transcriptional regulation mechanism in leukemic cells. Consistently, we found that primary progenitor cells with overexpressed WT1, and therefore reduced IRF8 expression, showed no detectable methylation of the investigated CpG islands (À278 to À564 bp). Therefore, we conclude that WT1-mediated repression of IRF8 does not depend on promoter methylation, although we cannot exclude that methylation may evolve with time after long-standing repression.
Although most reports of WT1 as a transcription factor emphasize the transactivation potential of WT1, growth factor receptors such as the epidermal growth factor receptor and insulin growth factor 1 receptor (IGFR-1), and also cell-cycle regulators such as cyclin E and ornithine decarboxylase and the enzyme telomerase RT are reported as repression targets of WT1 (reviewed in Yang et al. 18 ). Among the WT1 splice variants, the ÀKTS variant of the zinc-finger domain most often shows the strongest DNA binding, 45 and transcriptionally repressive domains in the amino-terminal of WT1 have been defined (reviewed in Lee and Haber 1 , Scharnhorst et al. 2 and in Yang et al. 18 ). In the present investigation, the WT1 þ 17AA/ÀKTS variant showed the strongest effects on IRF8 expression, but the other splice variants also, with the possible exception for WT1À17AA/ÀKTS, showed repressive effects on IRF8. Therefore, from present data, we cannot determine which domains in WT1 are critical for repression of IRF8. However, our finding that a WT1 mutant completely lacking the DNA-binding domain (WT1delZ) was without effect, strongly indicates that repression is dependent on DNA binding of WT1. Our finding that WT1
represses an IRF8-promoter luciferase reporter supports this notion. However, in the luciferase assay performed, only a rather weak repression (23%) on the proximal IRF8 promoter was observed. This might indicate that other regions, outside the analyzed 974 bp of the proximal promoter, contributes to repression of the endogenous gene. We found WT1 to systematically increase the expression of both SV40 (simian virus 40)-and TK (thymidine kinase)-driven renilla expression. Therefore, normalization of luciferase results would result in a much stronger apparent WT1-mediated repression of IRF8. As a consequence of this, we chose not to normalize the results, but rather to conduct a large number of independent experiments (n ¼ 7). Further experimental support for our identification of the WT1-binding site in the promoter, was given by our results from ChIP, performed with two distinct WT1 antibodies, showing an enrichment of the IRF8 promoter, as compared with the negative control sequence. Taken together, our data indicate a model in which WT1 itself directly binds to the IRF8 promoter and represses transcription, directly or through some corepressor molecule.
Early reports of overexpression of WT1 in a high proportion of various leukemias suggested a role for WT1 in leukemogenesis. [11] [12] [13] [14] Consistently, overexpression of WT1 interferes with differentiation of leukemic cells and WT1 can signal for survival and proliferation. 15, 46 Strong support for an oncogenic role of WT1 has recently been presented; WT1 induces a myeloproliferative disease in mice and cooperates with a leukemic fusion protein in the development of acute leukemia. 10 The mechanism by which WT1 contributes to leukemogenesis is unknown, but the presence of WT1 in several subtypes of chronic and acute leukemias suggests common mechanisms operating in several forms of leukemic cells. There is accumulating evidence for IRF8 as a tumor suppressor gene in myeloid neoplasms. IRF8-deficient mice develop a disease resembling CML with an expansion of the myeloid lineage, 22 and decrease of IRF8 levels is also implicated in acute leukemia. [25] [26] [27] In conclusion, we show that WT1 can mediate repression of IRF8 expression. Given the known antileukemic effects of IRF8, we propose that this mechanism may be a common way by which WT1 contributes to leukemogenesis.
